Financial Survey: Absci (ABSI) & Its Competitors

Absci (NASDAQ:ABSI) is one of 847 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Absci to similar businesses based on the strength of its dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Volatility & Risk

Absci has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. Comparatively, Absci’s peers have a beta of 0.90, meaning that their average stock price is 10% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Absci and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1	0	10	0	2.82
Absci Competitors	9766	14997	45286	1578	2.54

Absci presently has a consensus target price of $14.56, indicating a potential upside of 37.71%. As a group, “Biotechnology” companies have a potential upside of 92.40%. Given Absci’s peers higher probable upside, analysts plainly believe Absci has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Absci and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Absci	$1.56 million	N/A	-13.21
Absci Competitors	$105.26 million	-$42.92 million	-9.94

Absci’s peers have higher revenue, but lower earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

52.0% of Absci shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 10.5% of Absci shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Absci and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Absci	N/A	N/A	N/A
Absci Competitors	-14,339.21%	-509.11%	-45.42%

Summary

Absci beats its peers on 7 of the 12 factors compared.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.